Most adults who qualify for an RSV vaccine in the United States can get one at a pharmacy without a separate prescription from their doctor. Pharmacists in nearly every state have the authority to assess eligibility and administer adult vaccines directly, including the three FDA-approved RSV vaccines. The situation is more complicated for pregnant people receiving the maternal RSV vaccine and for infants who need the monoclonal antibody nirsevimab, where prescription requirements vary by state and by clinical setting.
How Adults Access the RSV Vaccine
If you are 60 or older, you can generally walk into a retail pharmacy, have a brief screening conversation with the pharmacist, and receive an RSV vaccine on the spot. This works much the same way as getting a flu shot or a shingles vaccine. Under federal law and most state pharmacy practice acts, pharmacists have independent authority to prescribe and administer vaccines to adults, so a separate visit to your doctor is not a prerequisite. The three vaccines currently approved for adults aged 60 and older are Arexvy (GSK), Abrysvo (Pfizer), and mResvia (Moderna).
That said, the fact that you can get the vaccine without a prescription does not mean every adult over 60 should automatically receive one. The recommendations specify which adults benefit most, and a pharmacist or your physician will help determine whether you fall into one of those groups. If you already have a primary care provider, they can also order and administer the vaccine during a routine visit. Either route works.
Who Is Recommended to Get Vaccinated
In June 2024, the Advisory Committee on Immunization Practices (ACIP) updated its RSV vaccine recommendations for adults. The new guidance recommends a single dose of any FDA-approved RSV vaccine for all adults aged 75 and older, and for adults aged 60 to 74 who have an increased risk of severe RSV disease. Risk factors that qualify someone in the 60-to-74 age group include chronic medical conditions like COPD, heart failure, or diabetes, moderate or severe immune compromise, and residence in a nursing home.1Morbidity and Mortality Weekly Report. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Adults who have already received one dose of any RSV vaccine should not get a second dose. Unlike flu shots, the RSV vaccine is currently a one-time immunization, not an annual one. This is an important practical point: if you got the shot during the 2023–2024 season under the earlier recommendation, you are already covered and do not need another.
Why the Recommendation Structure Changed
When RSV vaccines first became available in 2023, ACIP used a framework called “shared clinical decision-making” for all adults 60 and older. Under that approach, the decision to vaccinate was supposed to emerge from a conversation between patient and provider, weighing individual risk factors. In practice, providers found this confusing and time-consuming to implement, and vaccination coverage among adults with chronic health conditions was only modestly higher than among those without.2Morbidity and Mortality Weekly Report. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
The 2024 update replaced shared clinical decision-making with clearer, more traditional recommendation categories: a universal recommendation for everyone 75 and older, and a risk-based recommendation for those 60 to 74 with qualifying conditions. This shift matters for access because straightforward age-based and risk-based recommendations are easier for pharmacists to act on. When the guidance was vague, some pharmacists and insurance plans were unsure about who qualified, which contributed to slow uptake. By the end of 2023, RSV vaccination coverage among adults 60 and older was only about 17%.3Morbidity and Mortality Weekly Report. Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults — United States, Fall 2023 – Section: Results / Overall Vaccination Coverage and Intent
The Maternal RSV Vaccine and How Pregnant People Get It
A separate RSV vaccination pathway exists for pregnant people. In 2023, the FDA approved Abrysvo (Pfizer’s bivalent RSV prefusion F protein vaccine) for use during pregnancy to protect newborns against RSV infection in their first months of life.4PubMed Central. RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy The approved window for administration is between 32 weeks and 36 weeks and 6 days of gestation, which is narrower than the range studied in clinical trials because of a possible association between earlier vaccination and preterm birth.5PubMed Central. Longer interval between maternal RSV vaccination and birth increases placental transfer efficiency
In practice, most pregnant people receive this vaccine through their obstetrician or midwife during a prenatal visit rather than at a retail pharmacy. The vaccine is administered as part of prenatal care, and the provider handles the ordering and documentation. Whether this technically constitutes a “prescription” depends on the clinical setting. If your OB administers it directly, it functions more like any other in-office treatment. If they send you to a pharmacy, the pharmacy would need an order. Either way, this is not a vaccine you would typically seek out on your own at a drugstore. It requires coordination with your prenatal care team to ensure the timing falls within that narrow gestational window.
The logic behind maternal vaccination is that antibodies produced by the mother cross the placenta and protect the baby during the first several months of life, when RSV poses the greatest danger. A longer interval between the vaccination and birth allows more antibody transfer, which is why the timing window matters so much.
Nirsevimab for Infants and the Prescription Question
For infants, the main RSV prevention tool is nirsevimab (brand name Beyfortus), a monoclonal antibody given as a single injection. This is not technically a vaccine but rather a direct dose of protective antibodies. Whether a pharmacist can administer nirsevimab to an infant without a patient-specific prescription from a physician depends on where you live.
Some jurisdictions grant pharmacists independent authority to administer nirsevimab to infants, meaning parents can bring their baby to a pharmacy and have the pharmacist assess and administer the product. Other jurisdictions require a patient-specific prescription from a prescriber before a pharmacist can give it to an infant, even if that pharmacist has independent immunization authority for other age groups.6JAPhA Practice Innovations. Impact of pharmacist immunization authority on infant respiratory syncytial virus immunoprophylaxis rates This patchwork of rules means the answer to “do I need a prescription?” genuinely differs depending on your state.
If you are unsure about your local rules, calling your pediatrician’s office is the most reliable path. Most infants receive nirsevimab during a routine well-child visit anyway, where the pediatrician handles administration directly. The pharmacy route is more of a backup for families who have trouble accessing pediatric care or who miss the in-office window.
How Well the RSV Vaccines Work
The efficacy data for adult RSV vaccines is strong enough that the question of access has real stakes. A Cochrane systematic review of prefusion-based RSV vaccines in older adults found that they reduced RSV-associated lower respiratory tract illness by about 77% and RSV-associated acute respiratory illness by about 67%.7PubMed. Efficacy and safety of respiratory syncytial virus vaccines Individual trial data fills out the picture. Moderna’s mRNA-based vaccine (mResvia) showed roughly 84% efficacy against RSV-related lower respiratory tract disease with two or more symptoms in its pivotal trial.8PubMed. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults Pfizer’s Abrysvo showed similarly high first-season efficacy of about 86% against RSV-related lower respiratory tract disease in its RENOIR trial.9JAMA Network Open. Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease
A systematic review looking across all three approved vaccines found that Arexvy reduced RSV-related hospitalizations in older adults by roughly 60 to 65%, Abrysvo showed 58 to 63% efficacy in older adults and 68 to 72% protection against infant RSV hospitalization through maternal immunization, and mResvia demonstrated 55 to 58% efficacy against RSV illness. All three induced substantial increases in neutralizing antibodies lasting up to 12 months.10PubMed Central. Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia The variation between trials comes partly from differences in how outcomes were measured and the populations studied, but the overall message is consistent: these vaccines meaningfully reduce serious RSV disease in older adults.
Safety and the Guillain-Barré Signal
The most discussed safety concern with RSV vaccines is a small increased risk of Guillain-Barré syndrome (GBS), a rare neurological condition where the immune system attacks peripheral nerves. This signal emerged during post-marketing surveillance and has been confirmed by multiple analyses, though the absolute risk remains very low.
A study of England’s older adult RSV vaccination program estimated about 23 excess GBS cases per million doses, with researchers concluding that this risk was far exceeded by the vaccine’s benefits.11Nature Communications. Assessing the risk of Guillain-Barré syndrome in older adults after bivalent RSV pre-F vaccination in England A separate analysis among U.S. Medicare beneficiaries aged 65 and older found a somewhat lower attributable risk: roughly 6.5 to 9 excess GBS cases per million doses depending on the vaccine product. The FDA has maintained that the substantial benefits of RSV vaccination outweigh these identified risks.12medRxiv. Evaluation of Guillain-Barré syndrome following Respiratory Syncytial Virus Vaccination among Medicare Beneficiaries 65 Years and Older
Beyond the GBS signal, the common side effects are what you would expect from any vaccine. Injection site pain occurs in roughly a quarter of recipients, systemic symptoms like fatigue or muscle aches in under 10%, and serious adverse events in less than 1%.10PubMed Central. Evaluating the efficacy, safety, and immunogenicity of FDA-approved RSV vaccines: a systematic review of Arexvy, Abrysvo, and mResvia If you have a history of GBS, that is worth discussing with your provider before getting vaccinated, but for most people, the risk-benefit calculation is clearly favorable.
Insurance Coverage and Cost
For most adults with Medicare Part D or private insurance, RSV vaccines are covered as a preventive benefit, particularly now that ACIP has made standard age-based and risk-based recommendations. Under the Affordable Care Act, private insurers are generally required to cover ACIP-recommended vaccines without cost-sharing, though the timeline for implementing new recommendations can lag by up to a year after the recommendation is published. Medicare Part D has covered RSV vaccines since they were first recommended.
Without insurance, the out-of-pocket cost for an RSV vaccine runs roughly $200 to $300 per dose, depending on the product and the pharmacy. The manufacturers offer patient assistance programs for uninsured individuals, and the CDC’s Vaccines for Adults program (formerly the Bridge Access Program in its early form for COVID vaccines) may provide some support, though eligibility varies. If cost is a concern, ask the pharmacist directly about assistance options before assuming you cannot afford it.
When to Get Vaccinated
RSV follows a seasonal pattern in most of the United States, with cases rising in the fall and peaking in winter. The CDC generally recommends getting vaccinated before RSV season begins, ideally in late summer or early fall. Modeling work has suggested that seasonal vaccination programs are more cost-effective than year-round approaches in countries with defined RSV seasons.13BMC Medicine. Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis
Because the current adult RSV vaccines are one-time immunizations rather than annual shots, the timing question is mostly relevant for people who have not yet been vaccinated. If you missed the ideal pre-season window, getting vaccinated during RSV season still provides benefit, since it takes about two weeks for the immune response to build. There is no need to wait until the following year.
Why RSV Vaccines Took So Long to Arrive
RSV was identified as a major cause of respiratory illness in infants and older adults decades ago, yet vaccines did not reach the market until 2023. A major reason for this delay traces back to the 1960s, when a formalin-inactivated RSV vaccine tested in children actually made subsequent RSV infections worse, a phenomenon called vaccine-enhanced disease. That disaster stalled the entire field for years and forced researchers to rethink their approach from the ground up.14PubMed Central. Current concepts and progress in RSV vaccine development
The breakthrough came from structural biology. In 2013, researchers solved the three-dimensional structure of the RSV fusion (F) protein in its prefusion form, the shape it takes before it fuses with a human cell. This prefusion form turned out to be a far better target for generating protective antibodies than the postfusion shape that previous vaccine attempts had used. All three currently approved adult RSV vaccines are built around this prefusion F protein, and the Cochrane review confirmed that postfusion-based vaccines showed essentially no efficacy, validating the importance of the structural insight.7PubMed. Efficacy and safety of respiratory syncytial virus vaccines The gap between identifying the problem and solving it was about 50 years, which is sobering but also explains why these vaccines work as well as they do: they were built on an unusually deep understanding of the virus’s biology.
Coadministration With Other Vaccines
A common practical question is whether you can get the RSV vaccine at the same visit as your flu shot or updated COVID vaccine. The CDC allows coadministration of RSV vaccines with other adult vaccines, meaning you do not need to space them out with separate appointments. Each vaccine goes in a different injection site, typically one in each arm if you are getting two shots. Some people experience more soreness or fatigue when receiving multiple vaccines at once, but there is no evidence that coadministration reduces the effectiveness of any of the vaccines involved.
This flexibility is especially useful for older adults, since the fall season brings recommendations for flu, updated COVID, and (for the unvaccinated) RSV shots in a relatively short window. Being able to consolidate these into one or two pharmacy visits instead of three removes a real logistical barrier, particularly for people with mobility challenges or limited transportation. If you are due for more than one vaccine, mention it when you schedule your appointment, and the pharmacist can coordinate all of them at once.